in the first quarter of 2014, we announced the first quarter 2014 financial results of custirsen and our proprietary drug apatorsen. we continue to believe that our approach of targeting proteins that contribute to treatment resistance is critical in the fight against cancer. there are several exciting near-term milestones and our focus throughout the coming months will be the following : to announce borealis-1 results in the second half of this year ; to complete the first interim futility analysis for enspiRIT ; to complete enrollment of the f Finity trial of custirsen in second-line prostate cancer ; and to support enrollment efforts of the 6 ongoing phase 2 trials of apatorsen in 4 tumor types.